{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T17:32:53Z","timestamp":1791999173436,"version":"4.4.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,4,2]],"date-time":"2024-04-02T00:00:00Z","timestamp":1712016000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,2]],"date-time":"2024-04-02T00:00:00Z","timestamp":1712016000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The present study aimed at evaluating the YF-specific neutralizing antibody profile besides a multiparametric analysis of phenotypic\/functional features of cell-mediated response elicited by the 1\/5 fractional dose of 17DD-YF vaccine, administered as a single subcutaneous injection. The immunological parameters of each volunteer was monitored at two time points, referred as: before (Day 0) [Non-Vaccinated, NV<jats:sub>(D0)<\/jats:sub>] and after vaccination (Day 30\u201345) [Primary Vaccinees, PV<jats:sub>(D30\u201345)<\/jats:sub>]. Data demonstrated high levels of neutralizing antibodies for PV<jats:sub>(D30\u201345)<\/jats:sub> leading to a seropositivity rate of 93%. A broad increase of systemic soluble mediators with a mixed profile was also observed for PV<jats:sub>(D30\u201345)<\/jats:sub>, with IFN-\u03b3 and TNF-\u03b1 presenting the highest baseline fold changes. Integrative network mapping of soluble mediators showed increased correlation numbers in PV<jats:sub>(D30\u201345)<\/jats:sub> as compared to NV<jats:sub>(D0)<\/jats:sub> (532<jats:italic>vs<\/jats:italic>398). Moreover, PV<jats:sub>(D30\u201345)<\/jats:sub> exhibited increased levels of Terminal Effector (CD45RA<jats:sup>+<\/jats:sup>CCR7<jats:sup>\u2212<\/jats:sup>) CD4<jats:sup>+<\/jats:sup> and CD8<jats:sup>+<\/jats:sup> T-cells and Non-Classical memory B-cells (IgD<jats:sup>+<\/jats:sup>CD27<jats:sup>+<\/jats:sup>). Dimensionality reduction of Mass Cytometry data further support these findings. A polyfunctional cytokine profile (TNF-\u03b1\/IFN-\u03b3\/IL-10\/IL-17\/IL-2) of T and B-cells was observed upon in vitro antigen recall. Mapping and kinetics timeline of soluble mediator signatures for PV<jats:sub>(D30\u201345)<\/jats:sub> further confirmed the polyfunctional profile upon long-term in vitro culture, mediated by increased levels of IFN-\u03b3 and TNF-\u03b1 along with decreased production of IL-10. These findings suggest novel insights of correlates of protection elicited by the 1\/5 fractional dose of 17DD-YF vaccine.<\/jats:p>","DOI":"10.1038\/s41598-024-57645-3","type":"journal-article","created":{"date-parts":[[2024,4,2]],"date-time":"2024-04-02T05:01:44Z","timestamp":1712034104000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Comprehensive landscape of neutralizing antibody and cell-mediated response elicited by the 1\/5 fractional dose of 17DD-YF primary vaccination in adults"],"prefix":"10.1038","volume":"14","author":[{"given":"Laise Rodrigues","family":"Reis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ismael Artur","family":"Costa-Rocha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thais","family":"Abdala-Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Carolina","family":"Campi-Azevedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Peruhype-Magalh\u00e3es","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e1rcio Sobreira Silva","family":"Ara\u00fajo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine","family":"Spezialli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lis Ribeiro","family":"do Valle Antonelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosiane Aparecida","family":"da Silva-Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greg\u00f3rio Guilherme","family":"Almeida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eder Gatti","family":"Fernandes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francieli Fontana Sutile Tardetti","family":"Fantinato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla Magda Allan Santos","family":"Domingues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Cristina Ferreira","family":"Lemos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Chieppe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jandira Aparecida Campos","family":"Lemos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordana Grazziela","family":"Coelho-dos-Reis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheila Maria Barbosa","family":"de Lima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"de Souza Azevedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waleska Dias","family":"Schwarcz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luiz Ant\u00f4nio Bastos","family":"Camacho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"de Lourdes de Sousa Maia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiana Guimar\u00e3es","family":"de Noronha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Duault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yael","family":"Rosenberg-Hasson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9a","family":"Teixeira-Carvalho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holden Terry","family":"Maecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olindo Assis","family":"Martins-Filho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Collaborative Group for Studies of Yellow Fever Vaccine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dayane Andriotti","family":"Otta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olindo Assis","family":"Martins-Filho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,2]]},"reference":[{"key":"57645_CR1","doi-asserted-by":"publisher","first-page":"617","DOI":"10.5123\/s1679-49742017000300018","volume":"26","author":"K Cavalcante","year":"2017","unstructured":"Cavalcante, K. & Tauil, P. L. Risk of re-emergence of urban yellow fever in Brazil. Epidemiol. Serv. Saude 26, 617\u2013620. https:\/\/doi.org\/10.5123\/s1679-49742017000300018 (2017).","journal-title":"Epidemiol. Serv. Saude"},{"key":"57645_CR2","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/j.tim.2018.05.012","volume":"26","author":"F Douam","year":"2018","unstructured":"Douam, F. & Ploss, A. Yellow fever virus: Knowledge gaps impeding the fight against an old foe. Trends Microbiol. 26, 913\u2013928. https:\/\/doi.org\/10.1016\/j.tim.2018.05.012 (2018).","journal-title":"Trends Microbiol."},{"key":"57645_CR3","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.jcv.2014.08.030","volume":"64","author":"TP Monath","year":"2015","unstructured":"Monath, T. P. & Vasconcelos, P. F. Yellow fever. J. Clin. Virol. 64, 160\u2013173. https:\/\/doi.org\/10.1016\/j.jcv.2014.08.030 (2015).","journal-title":"J. Clin. Virol."},{"key":"57645_CR4","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1080\/21645515.2015.1082693","volume":"12","author":"AC Campi-Azevedo","year":"2016","unstructured":"Campi-Azevedo, A. C. et al. Booster dose after 10 years is recommended following 17DD-YF primary vaccination. Hum. Vaccines Immunotherap. 12, 491\u2013502. https:\/\/doi.org\/10.1080\/21645515.2015.1082693 (2016).","journal-title":"Hum. Vaccines Immunotherap."},{"key":"57645_CR5","doi-asserted-by":"publisher","first-page":"i3764","DOI":"10.1136\/bmj.i3764","volume":"354","author":"HC Maguire","year":"2016","unstructured":"Maguire, H. C. & Heymann, D. L. Yellow fever in Africa. BMJ 354, i3764. https:\/\/doi.org\/10.1136\/bmj.i3764 (2016).","journal-title":"BMJ"},{"key":"57645_CR6","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1001\/jamaophthalmol.2019.1956","volume":"137","author":"C Brand\u00e3o-de-Resende","year":"2019","unstructured":"Brand\u00e3o-de-Resende, C. et al. Characterization of retinopathy among patients with yellow fever during 2 outbreaks in Southeastern Brazil. JAMA Ophthalmol. 137, 996\u20131002. https:\/\/doi.org\/10.1001\/jamaophthalmol.2019.1956 (2019).","journal-title":"JAMA Ophthalmol."},{"key":"57645_CR7","unstructured":"PAHO\/WHO. Yellow Fever. https:\/\/www3.paho.org\/hq\/index.php?option=com_content&view=article&id=9476:yellow-fever&Itemid=0&lang=en#gsc.tab=0 (2015)."},{"key":"57645_CR8","unstructured":"WHO. Yellow Fever\u2014African Region (AFRO). https:\/\/www.who.int\/emergencies\/disease-outbreak-news\/item\/2022-DON405 (2022)."},{"key":"57645_CR9","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/s0140-6736(18)30152-1","volume":"391","author":"T Lancet","year":"2018","unstructured":"Lancet, T. Yellow fever: A major threat to public health. The Lancet 391, 402. https:\/\/doi.org\/10.1016\/s0140-6736(18)30152-1 (2018).","journal-title":"The Lancet"},{"key":"57645_CR10","unstructured":"WHO. Fractional Dose Yellow Fever Vaccine as a Dose-Sparing Option for Outbreak Response. https:\/\/www.who.int\/publications\/i\/item\/WHO-YF-SAGE-16-1 (2016)."},{"key":"57645_CR11","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1056\/NEJMoa1710430","volume":"381","author":"RM Casey","year":"2019","unstructured":"Casey, R. M. et al. Immunogenicity of fractional-dose vaccine during a yellow fever outbreak\u2014Final report. N. Engl. J. Med. 381, 444\u2013454. https:\/\/doi.org\/10.1056\/NEJMoa1710430 (2019).","journal-title":"N. Engl. J. Med."},{"key":"57645_CR12","doi-asserted-by":"publisher","first-page":"113568","DOI":"10.1016\/j.jim.2023.113568","volume":"522","author":"M Sim\u00f5es","year":"2023","unstructured":"Sim\u00f5es, M. et al. Standardization, validation, and comparative evaluation of a faster and high-performance test for quantification of yellow fever neutralizing antibodies. J. Immunol. Methods 522, 113568. https:\/\/doi.org\/10.1016\/j.jim.2023.113568 (2023).","journal-title":"J. Immunol. Methods"},{"key":"57645_CR13","unstructured":"OPAS\/OMS. Febre Amarela. https:\/\/www.paho.org\/pt\/topicos\/febre-amarela (2024)."},{"key":"57645_CR14","unstructured":"PAHO\/WHO. Brazil Launches World\u2019s Largest Campaign with Fractional-Dose Yellow Fever Vaccine. https:\/\/www3.paho.org\/hq\/index.php?option=com_content&view=article&id=14065:brazil-launches-worlds-largest-campaign-with-fractional-dose-yellow-fever-vaccine&Itemid=0&lang=en#gsc.tab=0 (2018)."},{"key":"57645_CR15","unstructured":"WHO. Yellow Fever Vaccine: WHO Position on the Use of Fractional Doses\u2014June 2017. https:\/\/www.who.int\/publications\/i\/item\/who-wer9225 (2017)."},{"key":"57645_CR16","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1186\/1471-2334-14-391","volume":"14","author":"AC Campi-Azevedo","year":"2014","unstructured":"Campi-Azevedo, A. C. et al. Subdoses of 17DD yellow fever vaccine elicit equivalent virological\/immunological kinetics timeline. BMC Infect. Dis. 14, 391. https:\/\/doi.org\/10.1186\/1471-2334-14-391 (2014).","journal-title":"BMC Infect. Dis."},{"key":"57645_CR17","doi-asserted-by":"publisher","first-page":"879","DOI":"10.4161\/hv.22982","volume":"9","author":"RM Martins","year":"2013","unstructured":"Martins, R. M. et al. 17DD yellow fever vaccine. Hum. Vaccines Immunotherap. 9, 879\u2013888. https:\/\/doi.org\/10.4161\/hv.22982 (2013).","journal-title":"Hum. Vaccines Immunotherap."},{"key":"57645_CR18","doi-asserted-by":"publisher","first-page":"4977","DOI":"10.1016\/j.vaccine.2014.07.021","volume":"32","author":"Collaborative Group for Studies on Yellow Fever Vaccines","year":"2014","unstructured":"Collaborative Group for Studies on Yellow Fever Vaccines. Duration of post-vaccination immunity against yellow fever in adults. Vaccine 32, 4977\u20134984. https:\/\/doi.org\/10.1016\/j.vaccine.2014.07.021 (2014).","journal-title":"Vaccine"},{"key":"57645_CR19","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/s1473-3099(01)00016-0","volume":"1","author":"TP Monath","year":"2001","unstructured":"Monath, T. P. Yellow fever: An update. Lancet Infect. Dis. 1, 11\u201320. https:\/\/doi.org\/10.1016\/s1473-3099(01)00016-0 (2001).","journal-title":"Lancet Infect. Dis."},{"key":"57645_CR20","doi-asserted-by":"publisher","first-page":"761","DOI":"10.7326\/m18-1529","volume":"169","author":"AHE Roukens","year":"2018","unstructured":"Roukens, A. H. E., van Halem, K., de Visser, A. W. & Visser, L. G. Long-term protection after fractional-dose yellow fever vaccination: Follow-up study of a randomized, controlled, noninferiority trial. Ann. Intern. Med. 169, 761\u2013765. https:\/\/doi.org\/10.7326\/m18-1529 (2018).","journal-title":"Ann. Intern. Med."},{"key":"57645_CR21","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.biologicals.2012.09.005","volume":"40","author":"M Sim\u00f5es","year":"2012","unstructured":"Sim\u00f5es, M. et al. Evaluation of accuracy and reliability of the plaque reduction neutralization test (micro-PRNT) in detection of yellow fever virus antibodies. Biologicals 40, 399\u2013404. https:\/\/doi.org\/10.1016\/j.biologicals.2012.09.005 (2012).","journal-title":"Biologicals"},{"key":"57645_CR22","doi-asserted-by":"publisher","first-page":"e1003458","DOI":"10.1371\/journal.ppat.1003458","volume":"9","author":"O Vratskikh","year":"2013","unstructured":"Vratskikh, O. et al. Dissection of antibody specificities induced by yellow fever vaccination. PLoS Pathog. 9, e1003458. https:\/\/doi.org\/10.1371\/journal.ppat.1003458 (2013).","journal-title":"PLoS Pathog."},{"key":"57645_CR23","doi-asserted-by":"publisher","first-page":"e49828","DOI":"10.1371\/journal.pone.0049828","volume":"7","author":"AC Campi-Azevedo","year":"2012","unstructured":"Campi-Azevedo, A. C. et al. 17DD and 17D\u2013213\/77 yellow fever substrains trigger a balanced cytokine profile in primary vaccinated children. PLoS ONE 7, e49828. https:\/\/doi.org\/10.1371\/journal.pone.0049828 (2012).","journal-title":"PLoS ONE"},{"key":"57645_CR24","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1111\/j.1365-2249.2006.03317.x","volume":"148","author":"MA Martins","year":"2007","unstructured":"Martins, M. A. et al. Activation\/modulation of adaptive immunity emerges simultaneously after 17DD yellow fever first-time vaccination: Is this the key to prevent severe adverse reactions following immunization? Clin. Exp. Immunol. 148, 90\u2013100. https:\/\/doi.org\/10.1111\/j.1365-2249.2006.03317.x (2007).","journal-title":"Clin. Exp. Immunol."},{"key":"57645_CR25","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.vaccine.2010.08.046","volume":"29","author":"ML Silva","year":"2011","unstructured":"Silva, M. L. et al. Characterization of main cytokine sources from the innate and adaptive immune responses following primary 17DD yellow fever vaccination in adults. Vaccine 29, 583\u2013592. https:\/\/doi.org\/10.1016\/j.vaccine.2010.08.046 (2011).","journal-title":"Vaccine"},{"key":"57645_CR26","doi-asserted-by":"publisher","first-page":"e0006462","DOI":"10.1371\/journal.pntd.0006462","volume":"12","author":"C Costa-Pereira","year":"2018","unstructured":"Costa-Pereira, C. et al. Multi-parameter approach to evaluate the timing of memory status after 17DD-YF primary vaccination. PLoS Negl. Trop. Dis. 12, e0006462. https:\/\/doi.org\/10.1371\/journal.pntd.0006462 (2018).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"57645_CR27","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1016\/j.vaccine.2021.12.029","volume":"40","author":"LR Reis","year":"2022","unstructured":"Reis, L. R. et al. Exploratory study of humoral and cellular immunity to 17DD yellow fever vaccination in children and adults residents of areas without circulation of yellow fever virus. Vaccine 40, 798\u2013810. https:\/\/doi.org\/10.1016\/j.vaccine.2021.12.029 (2022).","journal-title":"Vaccine"},{"key":"57645_CR28","doi-asserted-by":"publisher","first-page":"7919","DOI":"10.4049\/jimmunol.0803903","volume":"183","author":"RS Akondy","year":"2009","unstructured":"Akondy, R. S. et al. The yellow fever virus vaccine induces a broad and polyfunctional human memory CD8+ T cell response. J. Immunol. 183, 7919\u20137930. https:\/\/doi.org\/10.4049\/jimmunol.0803903 (2009).","journal-title":"J. Immunol."},{"key":"57645_CR29","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.3201\/eid2508.181432","volume":"25","author":"AC Campi-Azevedo","year":"2019","unstructured":"Campi-Azevedo, A. C. et al. 17DD yellow fever revaccination and heightened long-term immunity in populations of disease-endemic areas, Brazil. Emerg. Infect. Dis. 25, 1511\u20131521. https:\/\/doi.org\/10.3201\/eid2508.181432 (2019).","journal-title":"Emerg. Infect. Dis."},{"key":"57645_CR30","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.jim.2017.05.002","volume":"448","author":"AC Campi-Azevedo","year":"2017","unstructured":"Campi-Azevedo, A. C. et al. Heparin removal by ecteola-cellulose pre-treatment enables the use of plasma samples for accurate measurement of anti-Yellow fever virus neutralizing antibodies. J. Immunol. Methods 448, 9\u201320. https:\/\/doi.org\/10.1016\/j.jim.2017.05.002 (2017).","journal-title":"J. Immunol. Methods"},{"key":"57645_CR31","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.21769\/BioProtoc.1370","volume":"5","author":"D Lin","year":"2015","unstructured":"Lin, D., Gupta, S. & Maecker, H. T. Intracellular cytokine staining on PBMCs using CyTOF\u2122 mass cytometry. Bio Protoc. 5, 1370. https:\/\/doi.org\/10.21769\/BioProtoc.1370 (2015).","journal-title":"Bio Protoc."},{"key":"57645_CR32","doi-asserted-by":"publisher","first-page":"e1993","DOI":"10.1371\/journal.pone.0001993","volume":"3","author":"AH Roukens","year":"2008","unstructured":"Roukens, A. H. et al. Intradermally administered yellow fever vaccine at reduced dose induces a protective immune response: A randomized controlled non-inferiority trial. PLoS ONE 3, e1993. https:\/\/doi.org\/10.1371\/journal.pone.0001993 (2008).","journal-title":"PLoS ONE"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-57645-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-57645-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-57645-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,2]],"date-time":"2024-04-02T05:05:45Z","timestamp":1712034345000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-57645-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,2]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["57645"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-57645-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,2]]},"assertion":[{"value":"11 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7709"}}